Table AD7

Study 212

Mean (X) CGI-I (Values less than four represent improvement relative to time of screening)

LAST OBSERVATION CARRIED FORWARD ANALYSIS

Treatment Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

146

4.0

145

3.4

146

3.1

146

2.8

146

2.7

146

2.6

46

2.5

146

2.4

146

2.4

BUP SR 300 (II)

144

3.9

144

3.7

144

3.4

144

3.0

144

2.7

144

2.7

144

2.7

144

2.6

144

2.5

Placebo (P)

148

3.9

145

3.5

148

3.2

148

2.9

148

2.9

148

2.8

148

2.7

148

2.7

148

2.7

2-sided p-values for pairwise comparisons

L vs P

0.03

0.36

0.35

0.49

0.20

0.15

0.05

0.04

0.02

II vs P

> 0.6

0.02

0.02

0.29

0.21

0.70

0.67

0.39

0.26

OBSERVED CASES ANALYSIS

Treatment Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

146

4.0

145

3.4

136

3.1

133

2.8

133

2.6

122

2.5

118

2.3

117

2.3

110

2.2

BUP SR 300 (II)

144

3.9

144

3.7

136

3.4

131

2.9

121

2.6

111

2.5

104

2.4

104

2.2

101

2.2

Placebo (P)

148

3.9

145

3.5

140

3.2

132

2.9

124

2.8

117

2.7

114

2.5

107

2.5

100

2.4

2-sided p-values for pairwise comparisons

L vs P

0.03

0.36

0.20

0.59

0.27

0.27

0.16

0.24

0.06

II vs P

> 0.6

0.02

0.06

0.74

0.03

0.28

0.35

0.13

0.06